The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to ...
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback